BACKGROUND. Neuroendocrine tumors (NETs) of the pancreas are relatively uncommon tumors. The objective of this report was to describe the cytopathologic and immunocytochemical features of NETs obtained by endoscopic ultrasound (EUS)‐guided fine‐needle aspiration (FNA). METHODS. Forty‐eight patients who were diagnosed with pancreatic NETs based on EUS‐guided FNA were studied retrospectively (from 2002 to 2007). Clinical data, EUS findings, cytopathologic features, and immunocytochemical stains were reviewed for this study. The final histopathologic diagnosis from each patient also was available for comparison. RESULTS. Forty‐eight patients (28 men and 20 women) who ranged in age from 16 years to 86 years were selected and had the following clinical findings: solid or multiple pancreatic masses diagnosed by computed tomography or magnetic resonance imaging studies; simultaneous, suspicious, metastatic masses in the liver, mediastinum, and/or lung; hypoglycemia; multiple endocrine neoplasia type 1 syndrome; von Hippel‐Lindau syndrome; and primary NET of the small bowel. EUS findings revealed solid or multiple masses in the pancreatic head/uncinate, or in the pancreatic body/tail, or simultaneously in the pancreatic head/uncinate and body/tail. Cytologically, 40 patients were diagnosed with NETs (histopathogically confirmed), and 8 patients had findings that were suspicious of NETs (2 patients had false‐positive results, and 6 patients had histopathologically confirmed NETs). The most helpful cytologic findings for the diagnosis of NET were a richly cellular sample with a monotonous, poorly cohesive population of small or medium‐sized cells with granular chromatin (salt and pepper) and plasmacytoid morphology. Immunocytochemistry confirmed the neuroendocrine origin of tumors in 40 patients (material for immunocytochemistry was inadequate in 8 patients). CONCLUSIONS. The current results indicated that EUS‐guided FNA is a useful method for the diagnosis of pancreatic NETs. Cytopathologic examination in coordination with immunocytochemistry can provide an accurate diagnosis in most patients. Cancer (Cancer Cytopathol) 2008. © 2008 American Cancer Society.
We describe the clinical, imaging and cytopathological f e a t u r e s o f s o l i d p s e u d o p a p i l l a r y t u m o r o f t h e pancreas (SPTP) diagnosed by endoscopic ultrasoundguided (EUS-guided) fine-needle aspiration (FNA). A 17-year-old woman was admitted to our hospital with complaints of an unexplained episodic abdominal pain for 2 mo and a short history of hypertension in the endocrinology clinic. Clinical laboratory examinations revealed polycystic ovary syndrome, splenomegaly and low serum amylase and carcinoembryonic antigen (CEA) levels. Computed tomography (CT) analysis revealed a mass of the pancreatic tail with solid and cystic consistency. EUS confirmed the mass, both in body and tail of the pancreas, with distinct borders, which caused dilation of the peripheral part of the pancreatic duct (major diameter 3.7 mm). The patient underwent EUS-FNA. EUS-FNA cytology specimens consisted of single cells and aggregates of uniform malignant cells, forming microadenoid structures, branching, papillary clusters with delicate fibrovascular cores and nuclear overlapping. Naked capillaries were also seen. The nuclei of malignant cells were round or oval, eccentric with fine granular chromatin, small nucleoli and nuclear grooves in some of them. The malignant cells were periodic acid Schiff (PAS)-Alcian blue (+) and immunocytochemically they were vimentin (+), CA 19.9 (+), synaptophysin (+), chromogranin (-), neuro-specific enolase (-), a1antitrypsin and a1-antichymotrypsin focal positive. Cytologic findings were strongly suggestive of SPTP. Biopsy confirmed the above cytologic diagnosis. EUSguided FNA diagnosis of SPTP is accurate. EUS findings, cytomorphologic features and immunostains of cell block help distinguish SPTP from pancreatic endocrine tumors, acinar cell carcinoma and papillary mucinous carcinoma.
Different types of benign or malignant cystic lesions can be observed in the pancreas. Pancreatic cystic lesions are classified under pathology terms into simple retention cysts, pseudocysts and cystic neoplasms. Mucinous cystic neoplasm is a frequent type of cystic neoplasm and has a malignant potential. Serous cystadenoma follows in frequency and is usually benign. Intraductal papillary mucinous neoplasms are the most commonly resected cystic pancreatic neoplasms characterized by dilated segments of the main pancreatic duct and/or side branches, the wall of which is covered by mucus secreting cells. These neoplasms can occupy the pancreatic head or any part of the organ. Solid pseudopapillary tumor is rare, has a low tendency for malignancy, and is usually located in the pancreatic body or tail. Endoscopic ultrasound with the use of fine-needle aspiration and cytology permits discrimination of those lesions. In this review, the main characteristics of those lesions are presented, as well as recommendations regarding their follow up and management according to recent guidelines.
Metastatic lesions of the pancreas are uncommon, accounting for approximately 2% of pancreatic malignancies. Many tumours involve the pancreas secondarily and may manifest with different clinical and imaging characteristics. Although many patients have widespread disease, isolated metastases can be found. Surgical management is associated with improved survival in these cases. The experience of the pancreatic surgery unit and imaging department of our hospital in many patients presenting with pancreatic metastases is presented, and a review of the recent literature is undertaken. Main Messages• The early recognition of secondary pancreatic tumours on US, CT and MRI is extremely important.• Pancreatic metastases may mimic primary pancreatic adenocarcinoma or induce acute pancreatitis.• Most pancreatic metastases are discovered on a CT examination performed for follow-up.
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare and heterogeneous group of tumors presenting as localised or metastatic disease and in a subset with distinct clinical syndromes. Treatment is aimed at controlling the functional syndrome, eradicating the tumor, and/or preventing further tumor growth. Surgery is the treatment of choice in removing the primary tumor and/or reducing tumor burden but cannot be applied to all patients. Somatostatin analogs (SS-analogs) obtain control of functional syndromes in the majority of GEP-neuroendocrine tumors (NETs); phase III trials have shown that SS-analogs can be used as first-line antiproliferative treatment in patients with slow-growing GEP-NETs. The role of the recently approved serotonin inhibitor, telotristat ethyl, and gastrin receptor antagonist, netazepide, is evolving. Streptozotocin-based chemotherapy has been used for inoperable or progressing pancreatic NENs but the orally administered combination of capecitabine/temozolomide is becoming more popular due to its better tolerability and potential effect in other GEP-NENs. Phase III trials have shown efficacy of molecular targeted therapies in GEP-NETs and of radionuclide treatment in patients with midgut carcinoid tumors expressing somatostatin receptors. Most patients will develop disease progression necessitating further therapeutic options. A combination of currently available treatments along with the molecular signature of each tumor will guide future treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.